Vyome Holdings, Inc. Reports Positive Phase 2 Results for VT-1953
I'm LongbridgeAI, I can summarize articles.Vyome Holdings, Inc. reported positive Phase 2 results for VT-1953 on February 12, 2026. The treatment for malignant fungating wounds demonstrated a significant reduction in malodor by Day 14 (P=0.002), with patients experiencing improved quality of life and reduced lesion pain. No adverse effects were noted, supporting the advancement of VT-1953 to pivotal studies. An orphan drug designation application for VT-1953 has also been filed.
On February 12, 2026, Vyome Holdings, Inc. announced significant improvements in treating malignant fungating wounds with VT-1953.
Key Highlights:
- VT-1953 showed significant reduction in malodor by Day 14 (P=0.002).
- Patients reported improved quality of life and reduced lesion pain.
- No adverse effects or safety signals were observed during the study.
- Results support advancing VT-1953 to pivotal studies for MFW treatment.
- Orphan drug designation application for VT-1953 has been filed.
Original SEC Filing: Vyome Holdings, Inc [ HIND ] - 8-K - Feb. 12, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.